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Abstract
Glaucoma, the most common cause of irreversible blindness, is a neuropathy commonly initiated by pathological ocular
hypertension due to unknown mechanisms of trabecular meshwork degeneration. Current antiglaucoma therapy does not
target the causal trabecular pathology, which may explain why treatment failure is often observed. Here we show that the
chemokine CXCL12, its truncated form SDF-1(5-67), and the receptors CXCR4 and CXCR3 are expressed in human
glaucomatous trabecular tissue and a human trabecular cell line. SDF-1(5-67) is produced under the control of matrix
metallo-proteinases, TNF-a, and TGF-b2, factors known to be involved in glaucoma. CXCL12 protects in vitro trabecular cells
from apoptotic death via CXCR4 whereas SDF-1(5-67) induces apoptosis through CXCR3 and caspase activation. Ocular
administration of SDF-1(5-67) in the rat increases intraocular pressure. In contrast, administration of a selective CXCR3
antagonist in a rat model of ocular hypertension decreases intraocular pressure, prevents retinal neurodegeneration, and
preserves visual function. The protective effect of CXCR3 antagonism is related to restoration of the trabecular function.
These data demonstrate that proteolytic cleavage of CXCL12 is involved in trabecular pathophysiology, and that local
administration of a selective CXCR3 antagonist may be a beneficial therapeutic strategy for treating ocular hypertension and
subsequent retinal degeneration.
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Introduction
Primary open-angle glaucoma affects about 70 million people
and is predicted to account for over 11 million cases of blindness
by 2020 [1,2]. Its prevalence continues to increase as the
population ages. Glaucoma is a retinal neuropathy characterized
by retinal ganglion cell death. Pathological elevation of intraocular
pressure (IOP), namely ocular hypertension (OHT), is the most
critical risk factor for both the development and the progression of
the disease [3]. OHT is often diagnosed several years before
detecting the neuropathy. It is attributed to a decrease in
trabecular meshwork (TM) outflow facility to aqueous humor
(AH) caused by tissue degeneration whose primary mechanisms
are still unclear. Classical antiglaucoma treatments reduce the
abnormally elevated IOP but do not target directly the initial TM
pathology. In clinical practice, progressive therapeutic inefficiency
in controlling both the elevation of IOP and neuropathy often
occurs [4]. The lack of specific therapies for the TM pathology,
which is still developing in well-treated patients, could be
responsible for progressive treatment inefficiency coupled with
neuropathy worsening and sometimes blindness.
TM degeneration has largely been demonstrated as the main
cause of aqueous outflow resistance leading to OHT in primary
open-angle glaucoma (5]. The main glaucoma-related trabecular
modifications resemble age-related TM degeneration and involve
accumulation of trabecular extracellular matrix together with a
decrease in TM cellularity as previously described by our group
and others [6–9]. Trabecular cell (TC) loss that occurs in
glaucoma is known to develop through apoptotic phenomena
and was found as a characteristic of primary open-angle glaucoma
[10], but its causal mechanisms are still unknown.
Stromal cell-derived factor-1 (SDF-1), termed CXCL12,
belongs to the CXC subfamily of chemokines. CXCL12 is known
to bind mainly to a G-protein coupled receptor, CXCR4.
Recently, CXCR7 has been identified as an additional receptor
for CXCL12 [11–13]. Interestingly, CXCL12 is not only involved
in the immune system, but also in axonal development and
neurotransmission [14,15], migration, proliferation, and survival
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haematopoietic cells in bone marrow or damaged tissues
[17,18]. In the eye, CXCL12 and CXCR4 have been hypothe-
sized to play a role in neovascularization and in ocular
inflammation since they were detected in the retina [19,20], the
cornea [21], and the AH [22]. Matrix metalloproteinase (MMP)
proteolysis is one of the regulating factors for chemokine activity
[23,24]. Proteolytic processing of CXCL12 yields a wide variety of
amino-terminal truncated proteins that lose their ability to bind to
CXCR4 [25] as this chemokine–receptor interaction requires the
CXCL12 N-terminal residues [26]. One of the cleaved forms of
CXCL12, SDF-1(5-67), has been reported to induce neuronal
apoptosis during HIV brain infection [27]. Recently, SDF-1(5-67)
has been shown to bind specifically to another chemokine
receptor, CXCR3, where it induces direct neuronal apoptosis
[28].
In the present study, highly selective non-peptide antagonists of
CXCR3 and CXCR4 were studied for their effects on OHT and
related retinal neurodegeneration. We show that ocular adminis-
tration of a CXCR3 antagonist lowers IOP, prevents retinal
ganglion cell degeneration, and protects visual function in an
animal model of OHT. The chemokine and both receptors were
detected in human glaucomatous trabecular tissue and a
trabecular cell line. SDF-1(5-67) was found to be produced by
trabecular cells under the control of MMPs and cytokines known
to be involved in glaucoma. We demonstrate that SDF-1(5-67)
induces TC apoptosis through CXCR3, and that blocking
CXCR3 restores the filtrating function of the TM and protects
the retina against OHT-related degeneration. Collectively, the
results suggest that pathological enhancement of a SDF-1(5-67)/
CXCR3 interaction is involved in trabecular degeneration and
this chemokine/chemokine receptor axis may represent a new
therapeutic target to prevent the deleterious effect of OHT on the
visual function.
Methods
Reagents
Recombinant human CXCL12 (7.8 kDa), TNF-a (17.5 kDa),
TGF-b2 (12.8 kDa), CXCL10 (8.7 kDa) and TIMP-1 (20.6 kDa)
were obtained from R&D Systems (Minneapolis, MN, USA).
CXCL11 (8.3 kDa) was obtained from Preprotech (Rocky Hill, NJ,
USA). Exogenous CXCL12 and truncated SDF-1(5-67) (7.4 kDa)
were synthesized by F. Baleux. NBI-74330, a non-peptide antag-
onistofCXCR3[29,30],andAMD-3100,anon-peptideantagonist
of CXCR4 [31], were synthesized by Orga-Link (Gif-sur-Yvette,
France). Batimastat was a gift from E. Gabison and S. Menashi
(CNRS UMR 7149, University of Paris 12, Cre ´teil, France). Cell
antigens (Ag) were detected in TCs using the following antibodies
(Ab): mouse IgG1 anti-human CXCL12 mAb (1:200, clone 79018,
R&D Systems), mouse IgG2B anti-human CXCR4 mAb (1:200,
clone 44716, R&D Systems), mouse IgG1 anti-human CXCR3
mAb (1:200, clone 49801, R&D Systems), anti-caspase 3 (clone 92-
605, BD Biosciences), secondary antibodies Alexa Fluor488 goat
anti-mouseIgG(1:500,MolecularProbes,Montluc ¸on,France),and
FITC-conjugated goat anti-mouse Fab (1:500, DakoCytomation,
Glostrup, Denmark). Rat TM were assessed for inflammatory cell
infiltration using primary rabbit anti-CD45 pAb (1:100, ab10558.
Abcam, Cambridge, MA, USA) and mouse anti-rat CD11b mAb
(1:200, ab8879, Abcam). Anti-SDF-1(5-67) (1:100) was a generous
gift from C. Overall (University of British Columbia, Vancouver,
Canada), and anti-CXCR7 (1:200) was given by M. Thelen
(Institute for Research in Biomedicine, Bellinzona, Switzerland).
Isotype-matched antibodies from R&D Systems were used as
negative controls.
Human Trabecular Meshwork Specimens
Human TMs were obtained from 15 patients undergoing
surgery for primary open-angle glaucoma. All patients included in
the study were diagnosed for glaucoma at least 1 year before and
presented no other ocular pathology or systemic disease. The TM
was selectively removed during non-penetrating deep sclerectomy.
Experiments were conducted in the Clinical Investigation Centre
for Ocular Surface Pathology (Centre Hospitalier National
d’Ophtalmologie des Quinze-Vingts, Paris, France) in accordance
with the Declaration of Helsinki, Scotland amendment, 2000.
National ethics committee approval was obtained (INSERM-
DHOS CIC, 503) and all patients signed the informed consent
form before surgery.
Human Glaucomatous Trabecular Cell Line
For in vitro experiments, the human glaucomatous TC line
HTM3 was used, which has been previously characterized [32].
HTM3 cells were routinely cultured in standard humidified 5%
CO2 atmosphere in serum-free Dulbecco’s Modified Eagle
Medium (DMEM. GIBCO, Invitrogen, Carlsbad, CA, USA)
supplemented with 4 mM L-glutamine, 10% fetal bovine serum,
and 50 mg/mL gentamicin. For passages, monolayers were rinsed
with PBS, dislodged by trypsinization (0.25% trypsin, 0.02%
EDTA), then cultured from an initial concentration of 60,000
cells/mL. For immunofluorescence, TCs were grown on 22-mm
glass cover-slips, then dried and fixed in 4% paraformaldehyde for
15 min. All cells were used at passage 10 to 20.
Animal Model
Male 8-week-old Long-Evans rats weighing 300–350 g were
used. Animals were kept in pathogen-free conditions with food and
wateravailableadlibitumandhousedina12-hlight/12-hdarkcycle.
Ocularintegritywascheckedusingtheslitlampbiomicroscope.The
surgical model of OHT was induced in the right eye of each rat by
cauterization of three episcleral veins after conjunctival dissection
under general anesthesia (intraperitoneal injection of ketamine
75 mg/kg and xylazine 10 mg/kg) as reported elsewhere [33]. The
lefteyesunderwentconjunctivaldissectiononlyascontrols.Afterthe
surgery, the animals were maintained for a 21-day period and
monitored for IOP three times a week using a handheld tonometer
(TonoLab, Medtronics, Jacksonville, FL, USA) without sedation.
AnimalspresentingloworinstableIOPwerethenexcluded,andthe
experiments were carried out at least one month after the surgery.
Institutional review board approved the animal ethics for this study.
All experiments were conducted in accordance withthe Association
forResearchinVisionandOphthalmologyfortheUseofAnimalsin
Ophthalmic research.
Real-time PCR
mRNA levels in human tissues and TC line were assessed using
RT 7300 (Applied Biosystems) and assays-on-demand primers for
human CXCL12 (ID Hs00171022m1), human CXCR4 (ID
Hs00607978s1), and human CXCR3 (ID Hs00171041m1). Total
mRNA was isolated from cultured TCs using the NucleoSpin
RNA II extraction kit (Macherey-Nagel, Du ¨ren, Germany), and
was then reverse-transcribed (TaqMan Reverse Transcription
Reagents, Applied Biosystems). mRNA in human TM tissue was
extracted using the NucleoSpin RNA XS kit (Macherey-Nagel),
then conditioned and determined following the same above-
described procedure. Relative quantitation of target genes was
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ized to an endogenous control S18 gene and relative to a calibrator
after calculating the efficiency coefficient. The results are
presented as the inverse of the normalized Ct value (InvCt) or as
the relative fold change compared to unstimulated control. A
negative control was routinely used omitting mRNA from the RT
reaction mixture.
Immunohistofluorescence
Protein expression of CXCR3, CXCR4, and CXCL12 was
detected in tissues and in the HTM3 cell line by indirect immuno-
fluorescence using a laser confocal microscope (E800, PCM2000,
Nikon, Champigny-sur-Marne, France). Nonspecific Ab binding
was blocked with normal goat serum or with fetal bovine serum in
PBS/0.1% Triton for 60 min, washed three times, then incubated
overnight at 4uC with primary Ab. After three more washes, cells
were counterstained with secondary fluorescent Ab for 2 h at
room temperature. Specimens were finally washed three times in
PBS, incubated in propidium iodide for 3 min (Sigma-Aldrich,
France) or in DAPI for 1 min, and mounted in gel mounting
medium. Isotype-matched mAbs were used as controls for each
sample and each primary Ab.
Flow Cytometry
Total and cell membrane surface expression of proteins was
analyzed on a FC 500 flow cytometer (Beckman Coulter, Miami,
FL, USA). TCs (120,000 per well) were plated in six-well plates
(Costar, Cambridge, MA, USA) and grown to 80% confluence.
The cells were cultured in complete medium for 24 h and
subsequently incubated with serum-free DMEM, supplemented
CXCL12, or SDF-1(5-67) for 12 h. Cells were carefully detached,
suspended in PBS containing 1% BSA, blocked with normal rabbit
serum, and stained with primary Ab for 1 h on ice, washed three
times with cold 1% BSA PSB, followed by counterstaining with the
corresponding fluorescein isothiocyanate-conjugated secondary
antibody (DakoCytomation) for 30 min. Cells were preincubated
and immunostained adding or not 0.5 mg/mL saponin in order to
determine total or surface expression respectively. Isotype-
matched antibodies were used as negative controls. For each
specimen, at least 1,000 cells per antibody were analyzed. The
results are reported as mean fluorescence intensity (MFI)
normalized to isotypic control.
ELISA
The amount of CXCL12 released into TC supernatants was
measured by an in-house ELISA kit (ref. DY350, R&D Systems).
Cells were cultured and stimulated as described above, and
supernatants were isolated after centrifugation. 96-well microtitre
plates were coated overnight with mouse anti-CXCL12 capture
mAb then nonspecific binding was blocked for 2 h with 1% BSA
in PBS. Duplicate samples (100 mL) of cell supernatants or serial
dilutions of standards of human recombinant CXCL12 were
incubated for 2 h, washed, then incubated with goat anti-
CXCL12 mAb for 2 h, followed by 20-min incubation with
HRP-conjugated streptavidin. Reaction product was detected
using color reagent (ref. DY999, R&D Systems). Optical density
was read (450–570 nm, SpectraFluor, TECAN, Switzerland) and
averaged from ten measurements per well. The limit of sensitivity
for this assay was 15 pg/mL.
Western Blot Analysis
Protein extracts were prepared from TCs (120,000 cells per
well) grown to 80% confluence in six-well plates. The cells were
maintained with medium for 24 h, then incubated subsequently
for 24 h with supplemented DMEM only or with specific
inhibitors, detached and homogenized in cell lysis buffer. Equal
amounts of proteins were separated on 4%–12% Tris-Glycine gel
(Novex, Invitrogen), transferred to nitrocellulose, and probed
overnight with anti-SDF-1(5-67) neoepitope polyclonal antibody
(1:100, 30-min preincubated with CXCL12 to improve the
antibody specificity) following carefully the same procedure as
previously described [28]. Primary Ab binding was revealed using
HRP-conjugated goat anti-rabbit IgG (1:3000, Vector, AbCys,
Paris, France) for 1 hour and developed with ECL Plus detection
reagents (GE healthcare, Orsay, France). b-actin (Abcam) was
used as internal control. Signal intensity of anti-SDF-1(5-67)
binding was quantitated using ImageJ software and normalized to
b-actin detection. Recombinant CXCL12 and SDF-1(5-67) were
used in Western Blots in order to control the antibody for
specificity against SDF-1(5-67) neoepitope only.
TUNEL Labeling
A terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) assay (Roche Diagnostics, Meylan, France)
was performed to detect apoptosis in rat eye cryosections following
the manufacturer’s instructions. Controls were done in each eye
using a 10-min pretreatment with DNAse or omitting the
transferase solution as positive or negative control, respectively.
Specimens were mounted in aqueous mounting medium with
DAPI to be further analyzed using light epifluorescence micros-
copy. TUNEL-labeled TCs were observed and counted in five
0.01 mm
2 fields per sample in order to compare apoptotic TC
density between groups. TUNEL-labeled retinal ganglion cells
were counted in five fields per sample and normalized to the
observed retinal inner layer length.
Cell Viability Assays
The effects of CXCL12 and SDF-1(5-67) on the cell prolifer-
ation and apoptosis were analyzed in a previously used cellular
model of toxicity [34]: 80% confluent TCs were incubated in PBS
with 0.01% benzalkonium chloride for 15 min in order to induce
approximately 50% apoptosis. Cells were washed with PBS,
incubated in free medium (control) or with CXCL12, SDF-1(5-
67), and inhibitors during a 24-h recovery period. Microplate
cytofluorometry was performed on Saphire Microplate reader
(Tecan Instruments, Lyon, France) in 96-well microtitre plates:
neutral red staining (Fluka, Ronkonkoma, NY, USA) was used to
evaluate membrane integrity that closely correlates with cell
viability [35]; apoptosis was quantified with the nuclear dye
Hoechst33258 (Hoechst, Germany) combined with propidium
iodide in order to exclude necrosis [36]. Apoptosis was calculated
as the ratio of apoptotic cells on the total cell viability, and
expressed as relative fold changes compared to control.
Animal Experiments
For evaluation of the effect of non-peptide antagonists on IOP,
forty animals presenting stable OHT were included and
randomly divided into four equal groups: in both eyes, ten rats
received one subconjunctival injection of the CXCR4 antagonist
AMD3100 (1 mM, 100 mL), ten received a single injection of the
CXCR3 antagonist NBI-74330 (1 mM, 100 mL), ten received one
injection of NBI-74330 followed by a second one 4 days after,
and ten rats received the vehicle only. IOP was monitored every
two days by an independent person i.e. who was blind to the
treatment. At the end of the experiments, animals were
euthanized and the eyes were immediately removed, fixed in
4% paraformaldehyde, embedded in an optimal cutting-temper-
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Pu ¨teaux, France) and cut into 15-mm cryosections. For the NBI-
74330 dose-response study, twenty animals presenting stable
OHT were randomly divided into four equal groups to receive
either NBI-74330 injections (100 mL) at three different concen-
trations (0.01 mM, 0.1 mM, and 1 mM) or the vehicle only. IOPs
were averaged from days 6, 8, and 10.
For the evaluation of AH outflow, twenty animals presenting
stable OHT were randomly divided into two equal groups to
receive either NBI-74330 injections (1 mM, 100 mL) or the vehicle
only. AH outflow was assessed at day 8 using in vivo fluoropho-
tometry [37,38]. Briefly, 1 mL fluorescein was injected using a 33G
needle into the anterior chamber under general anesthesia. One
hour after, AH decrease in anterior chamber fluorescence has
been recorded in vivo for 30 minutes using Micron III fluorescent
imaging device (Phoenix research laboratories, San Ramon, CA)
and ImageJ software (NIH). Mean fluorescence intensities were
normalized to the initial intensity and drawn in semi-log graphs as
a function of time in order to calculate the AH outflow depending
on the curve slope. To label the hydrodynamic patterns of
trabecular outflow passage, ocular perfusion of fluorescent
microsphere was performed as reported elsewhere [39,40]. Ocular
anterior chamber was exchanged with red-fluorescent micro-
spheres in BSS (0.1 mm, 0.02%v/v, Invitrogen) using a double
30G needle infusion, and followed by a 30-minute perfusion at the
IOP measured before death. Anterior chamber contents were
washed with BSS and eyes were immediately removed and fixed in
4% paraformaldehyde for 15 minutes. Anterior segments were
quadrisected and flat-mounted on coverglass after exposing the
TM by gently moving the iris tissue. TM was observed under laser
confocal microscope using a 206 objective lens regardless of the
presence of microsphere accumulation. An index of the trabecular
filtration, namely trabecular percent effective filtration length
(PEFL), was calculated as the length ratio of the zones wherein
tracer accumulated to the total length of the inner wall in at least 8
images per eye [39].
For the in vivo evaluation of retinal atrophy and visual function,
twenty animals with stable OHT were injected in one eye with
either NBI-74330 (1 mM, 100 mL) or vehicle (100 mM) following
the same protocol as described above. IOP was monitored once a
week. Retinal nerve fiber density was assessed in vivo 2 months after
the treatment using confocal scanning laser ophthalmoscopy
(HRA, Heidelberg Engineering, Heidelberg, Germany). The eyes
were dilated with 0.5% tropicamide and 0.5% phenylephrine
hydrochloride eye drops (Santen, Osaka, Japan). Each rat was
gently held manually to keep the eye in position for imaging the
retina. Dynamic retinal images were recorded in the center of the
fundus and in the four mildperipheral areas. The density of retinal
nerve fiber was calculated in each image and averaged using
Metamorph software (Molecular Device, Sunnyval, CA, USA).
Visual function was evaluated using an optokinetic apparatus
consisting of interchangeable circular drums with black and white
stripes rotating around a stationary holder in which the rat sits, as
previously described [41]. Rats were tested at spatial frequencies of
0.125, 0.25, and 0.5 cycles/degree (2 turns/minute) under
photopic conditions. Each rat was tested for one minute for each
eye and each frequency during one session. Digital recordings of
the head movements were analyzed and the amount of time the
rat spent head tracking was calculated separately for each eye in a
masked manner.
To study the effect of the chemokine on IOP, intraocular
injections with CXCL12 or SDF-1(5-67) (100 ng/mL [13 nM],
5 mL) or vehicle only were performed in ten normal rats. The IOP
was measured every 12 hours using Tonolab tonometer during five
days.
Statistical Analysis
All data in text and in bar graphs are reported as means 6 SEM
and represent at least three independent experiments. Analysis was
performed using NCSS software (NCSS, Kaysville, UT, USA).
Data were tested for distribution in order to perform the adequate
parametric (Student’s t-test or one-way ANOVA followed by
Tukey’s post hoc test) or nonparametric test (Mann-Whitney or
Kruskal-Wallis tests) for the comparisons. A value of P,0.05 was
considered to be significant.
Results
Human Glaucomatous Trabecular Tissue and A
Trabecular Cell Line Express CXCL12, SDF-1(5-67), CXCR3
and CXCR4
We first checked whether human glaucomatous trabecular
tissue and cells were able to express the chemokine and chemokine
receptors. CXCL12, CXCR3, and CXCR4 were detected by
immunofluorescence and flow cytometry in unstimulated cells
(Fig. 1A–E). mRNAs for CXCL12, CXCR3 and CXCR4 were
also detected in both human tissue and trabecular cell line
(Fig. 1F). Finally, TCs were able to release CXCL12 as
determined by ELISA of cell supernatants (22.865.28 pg/ml
[2.960.7 pM] from 100,000 cells/mL grown during 48 h).
Western blot analysis of unstimulated HTM3 cells, using a
polyclonal anti-SDF-1(5-67) neoepitope-specific antibody, identi-
fied SDF-1(5-67) (Fig. 2A,B). Incubation (24-h) with MMP
inhibitors batimastat (100 nM) or TIMP-1 (0.5 nM) significantly
reduced the amount of SDF-1(5-67), confirming that it originated
from MMP activity produced by TCs. 24-h incubation of TCs
with either TNF-a (50 ng/mL [2.9 nM]) or TGF-b2 (10 ng/mL
[0.8 nM]), both known to be involved in glaucoma, increased the
production of SDF-1(5-67) (Fig. 2A,B).
CXCL12 Protects TCs from Apoptotic Stress Whereas SDF-
1(5-67) Induces Apoptosis
In a TC model of toxic-induced apoptosis [34], addition of
CXCL12 (10 ng/mL [1.3 nM]) decreased apoptosis, whereas
SDF-1(5-67) (10 ng/mL [1.3 nM]) potentiated apoptosis (Fig. 3A).
Both the protective effect of CXCL12 and the deleterious effect of
SDF-1(5-67) were concentration-dependent, with a maximal effect
of either chemokine observed at 10 ng/mL (Fig. 3B).
SDF-1(5-67) Induces Apoptosis via CXCR3 and Caspase-3
Activation
In order to test that CXCL12 and its cleaved form were acting
via two different receptors, the effect of CXCL12/SDF-1(5-67) on
receptor cell membrane expression was assessed using flow
cytometry. We observed that exogenous CXCL12 (10 ng/mL
[1.3 nM], 6 h) downregulated cell surface expression of CXCR4
but not CXCR3. In contrast, stimulation with SDF-1(5-67)
reduced the membrane expression of CXCR3 but not CXCR4
(Fig. S1). TC expression of CXCR7, an additional CXCL12
receptor, was not affected by either CXCL12 or by SDF-1(5-67),
(160.2, 1.260.1, and 0.9560.05 for normalized mean fluores-
cence intensity in unstimulated, CXCL12- and SDF-1(5-67)-
stimulated cells, respectively). Blockade of CXCR4 with
AMD3100 (1 mM) inhibited the protective effect of CXCL12
and induced apoptosis, mimicking the apoptotic effect of SDF-1(5-
67) (Fig. 3C). I-TAC/CXCL11, a ligand for CXCR3 and
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and 1.0360.14 fold over control for a 24-h incubation with
CXCL11 at 1 ng/mL, 10 ng/mL, and 100 ng/mL respectively)
confirming that the protective effect of CXCL12 was mediated by
CXCR4. In contrast, selective blockade of CXCR3 with NBI-
74330 (1 mM) inhibited the apoptotic effect of SDF-1(5-67)
(10 ng/mL) (Fig. 3C). Moreover, 24-h incubation with CXCL10
(10 ng/mL [1.1 nM]), another ligand for CXCR3, induced cell
apoptosis that was prevented by NBI-74330. SDF-1(5-67)
increased active caspase-3 and this effect was also inhibited by
the CXCR3 antagonist (Fig. 3D).
In vivo Treatment with a CXCR3 Antagonist Reduces
Ocular Hypertension in a Rat Model of Ocular
Hypertension
In order to extent our in vitro data, we tested in vivo whether
CXCR3 and/or CXCR4 were implicated in the regulation of IOP
by using highly selective non-peptide antagonists of both
chemokine receptors in a rat model of OHT and related retinal
degeneration, which was induced by episcleral vein cauterization
[29]. AMD-3100 [31] (1 mM, 100 mL) or NBI-74330 [29,30]
(1 mM, 100 mL), selective antagonists for CXCR4 and CXCR3
respectively, were administrated in the subconjunctival space of rat
eyes. A single administration of NBI-74330 induced a decrease in
IOP 4 days after the treatment, reaching the normal IOP values
observed in normotensive control eyes (Fig. 4A). This decrease in
IOP was transient since IOP returned to elevated values of
untreated eyes after 6 days. When a second administration was
given at the time of maximal decrease, IOP remained low during a
period of 6 weeks (Fig. 4B). NBI-74330 reduced IOP in a dose-
dependent manner (Fig. 4C). In contrast, subconjunctival
administration of a CXCR4 selective antagonist did not influence
IOP in eyes with OHT (Fig. S2). In control eyes, the antagonists
had no effect. In parallel, CXCL12 and SDF-1(5-67) were tested
in normal rat eyes for their ability to modify IOP. CXCL12 ocular
injections had no significant effect on IOP, whereas two injections
of SDF-1(5-67) significantly increased IOP that remained elevated
for 3 days (Fig. S3).
Figure 1. CXCL12, CXCR3, and CXCR4 expression by human glaucomatous trabecular tissue and a trabecular cell line. (A–C) The
chemokine CXCL12 (A) and receptors CXCR3 (B) and CXCR4 (C) are detected in unstimulated human glaucomatous trabecular cells HTM3 by indirect
immunofluorescence (secondary antibody in green, propidium iodide in red, scale bar: 50 mm, magnification 6200). (D) Chemokine receptor CXCR4
appears as distinct spots located at the cell membrane surface (scale bar: 5 mm, mag. 6800). Representative images of three independent
experiments are depicted. (D) Cell expression of CXCL12 and receptors is also detected and quantified by immunoflowcytometry. Representative
results obtained over 6 independent experiments, mean 6 SEM of positive cells. (E) Chemokine and receptor mRNAs are detected in human
glaucomatous trabecular tissues (n=15) and in the HTM3 trabecular cell line. Data in the bar graph are presented as means 6 SEM.
doi:10.1371/journal.pone.0037873.g001
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Investigations were conducted in the anterior segment of the eye
in order to study mechanisms involved in the NBI-74330-related
decrease in IOP. In our animal model, we observed a decrease in
AH outflow together with a decrease in the TM filtrating surface
in hypertensive eyes compared to normotensive controls, one
month after the surgical procedure (Fig. 5A,B,C,D). AH outflow
impairment was significantly counteracted by treatment with NBI-
74330 (Fig. 5A). Furthermore, trabecular filtrating surface was
also significantly improved by the selective CXCR3 antagonist
(Fig. 5B,C,D). TC apoptosis was significantly detected in
hypertensive eyes as compared to normotensive controls
(Fig. 5E,F,G). In hypertensive eyes, apoptosis was significantly
decreased by NBI-74330 as compared to untreated eyes. There
was no inflammatory cell infiltration in the TM whatever the
group as revealed by a lack of either anti-CD45 or anti-CD11b
reactive cells. These data together suggested that blocking CXCR3
may lower OHT by restoring the trabecular filtrating function and
protecting directly TCs from apoptosis.
CXCR3 Antagonist Prevents Retinal Neuropathy and
Protects Visual Function
In parallel, OHT-related retinal degeneration and related visual
degradation were studied. In our animal model, retinal nerve fiber
density was significantly decreased in eyes with OHT compared to
controls three months after the surgery as assessed in vivo by
confocal scanning laser ophthalmoscopy (Fig. 6A). Eyes treated
with selective CXCR3 antagonist presented higher nerve fiber
density than untreated hypertensive eyes (Fig. 6A). Similarly, the
visual function was better in NBI-74330-treated eyes than in
untreated controls as assessed by optokinetic measurements
(Fig. 6B). Ex vivo, NBI-74330-related reduction in IOP was
associated with a decrease in retinal ganglion cell apoptosis as
assessed by TUNEL-labeling (Fig. 6C).
Discussion
Several recent data have demonstrated that chemokines are not
only involved in inflammatory/immune processes but also in the
regulation of tissue microenvironment as well as in degenerative
disorders [42]. In this study, we addressed the involvement of a
balance between the full length chemokine CXCL12 and its
truncatedformSDF-1(5-67)intheregulationofIOPbymodulating
theTMfiltrating functionviathechemokinereceptorsCXCR4and
CXCR3. We describe the successful use in vivo of a non-peptide
selectiveantagonistofCXCR3todecreaseelevatedIOPandprotect
the retina in an animal model of OHT, establishing this chemokine
receptor as a new therapeutic target to prevent the trabecular
degeneration and its deleterious effects on the visual function.
WereportthatCXCL12,CXCR3,andCXCR4areexpressedin
human trabecular tissue of glaucomatous patients as well as in a
human glaucomatous TC line. In the eye, CXCL12 mRNA has
been previously detected in TCs using gene microarrays [43];
CXCR4 has been investigated in the retina and in the cornea [19–
21] but not in the TM; no data are available on the expression of
CXCR3. TCs play a crucial role in IOP regulation because of their
phagocytic activity and their ability to produce extracellular matrix
components and MMPs [44,45]. It has been recently demonstrated
thatMMPcleavageofCXCL12yieldsatoxictruncatedform,SDF-
1(5-67), causing direct apoptosis via CXCR3 [27,28]. MMPs have
been reported to be significantly involved in mechanisms associated
with TM degeneration in primary open-angle glaucoma [46]. Here
we observed a basal production of SDF-1(5-67) by TCs, which
originatedfromMMPactivityonfulllengthCXCL12.Interestingly,
TNF-a and TGF-b2, cytokines known to be overexpressed in
glaucoma [47,48], increased the production of SDF-1(5-67). In vitro,
we described a constitutive autocrine function of CXCL12/
CXCR4 in TCs, as previously described in the brain [49], which
protected TCs against apoptosis. Indeed, a direct protective role of
fulllengthCXCL12hasbeenreportedinmeningioma[50]andina
primary neuronal cell line [51] without any involvement of
inflammatory cells. Recently, another chemokine receptor,
Figure 2. Human glaucomatous trabecular cells produce SDF-1(5-67). (A,B) SDF-1(5-67), a truncated form of CXCL12, is detected in the
human glaucomatous trabecular cell line HTM3 using a specific anti-SDF-1(5-67) neoepitope antibody. MMP inhibitors batimastat (100 nM) and TIMP-
1 (0.5 nM) induce a decrease in SDF-1(5-67) production, whereas TNF-a (50 ng/mL [2.9 nM]) and TGF-b2 (10 ng/mL [0.8 nM]) enhance the production
of SDF-1(5-67). ** P,0.01. Exogenous SDF-1(5-67) and CXCL12 were used as positive and negative controls respectively for the antibody specificity as
presented in the upper membrane (controls) of a representative western blot (A) taken from three independent experiments. Data in bar graphs are
presented as means 6 SEM.
doi:10.1371/journal.pone.0037873.g002
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[11–13]. In TCs, we observed a very low expression of CXCR7
which was not influenced by exposure to CXCL12; I-TAC/
CXCL11, a reported ligand for CXCR7, was further unable to
influence TC viability. In contrast, we observed that SDF-1(5-67)
inducedTCapoptosisthroughCXCR3andactivationofcaspase-3.
TheinvolvementofCXCR3inTCapoptosiswasfurtherconfirmed
by the use of NBI-74330 that inhibited the apoptotic effect of SDF-
1(5-67), and by the use of IP-10/CXCL10, a cognate ligand for
CXCR3, that mimicked its effect. However, the lack of effect of
CXCL11 is intriguing since it is also one of the ligands for CXCR3.
It could be explained, at least in part, by the fact that CXCL11
affinityisfive-foldlowerthanthatofCXCL10forthesplicedvariant
CXCR3-B, which is likely to be expressed by TCs [52]. Together
our results suggest that SDF-1(5-67)-CXCR3 interaction induced
TClossthroughapoptoticmechanisms.Recently,Zhuetalreported
that this interaction was also involved in autophagy suppression in
neurons [53]. Though nothing is known about autophagic
mechanisms involved in the trabecular degeneration, such a
phenomenon cannot be excluded.
We thus decided to test selective chemokine receptor antagonists
inaratmodelofOHTinordertodetermineifCXCR3andCXCR4
are involved in the trabecular pathology. Ophthalmic treatment
withAMD-3100,anon-peptideselectiveantagonistofCXCR4,had
no effect on IOP. On the contrary, NBI-74330, a non-peptide
selectiveantagonistofCXCR3,inducedadose-dependentdecrease
in IOP and prevented retinal nerve fiber degeneration responsible
forvisionlossinhypertensiveeyes.NBI-74330hasbeendescribedas
a highly selective antagonist for CXCR3 in human and rodent cells
[28,29,54,55]. It was used in vivo to reduce atherosclerosis plaque
formation in mice [56] and to slow growth of glioblastoma [57]. To
our knowledge, this is the first study reporting the successful use of
NBI-74330 for the treatment of an ocular disease.
Weperformedepiscleralveincauterizationinrateyeswhichleads
toastableOHTformonthsandtoretinaldegenerationaspreviously
described [32,58,59]. While there is still a lack of accurate and
validatedanimalmodelsforglaucoma,weusedthismodelbecauseit
shares several features with human primary open-angle glaucoma
[60]: (i) it induces long-term OHT by reducing AH outflow without
surgically damaging the TM; (ii) it does not modify the anterior
Figure 3. CXCL12 protects trabecular cells from apoptosis via CXCR4, whereas SDF-1(5-67) induces apoptosis through CXCR3 and
caspase-3 activation. (A) 24-h incubation with CXCL12 (10 ng/mL [1.3 nM]) protects HTM3 cells from apoptotic stress induced by 15-min exposure
to 0.01% benzalkonium chloride (BAC), whereas SDF-1(5-67) (10 ng/mL [1.3 nM]) increases apoptosis as assessed by microplate cytometry using
Hoechst dye. ** P,0.05 vs. unstressed cells, 1 P,0.05 and 11 P,0.01 vs. BAC-exposed cells. (B) The protective effect of CXCL12 (10 ng/mL, 24 h) is
reversed by CXCR4 antagonist (AMD-3100, 1 mM), whereas the apoptotic effect of SDF-1(5-67) (10 ng/mL, 24 h) is inhibited by CXCR3 antagonist (NBI-
74330, 1 mM). CXCL10 (10 ng/mL [1.1 nM], 24 h), a conventional ligand for CXCR3, mimics the apoptotic effect of SDF-1(5-67). ** P,0.01. (C) Dose-
dependent effect of 24-h incubation with SDF-1(5-67) or with CXCL12. ** P,0.01 vs. CXCL12. (D) SDF-1(5-67) (10 ng/mL) increases caspase-3
activation as assessed by immunoflowcytometry. CXCR3 antagonist (NBI-74330, 1 mM) inhibits SDF-1(5-67)-induced caspase 3 activation. ** P,0.01
vs. unstimulated, 11 P,0.01 vs. SDF-1(5-67)-stimulated. Data in graphs are presented as means 6 SEM.
doi:10.1371/journal.pone.0037873.g003
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associated with retinal nerve fiber defects and retinal ganglion cell
apoptotic loss. In this animal model of OHT and OHT-related
retinal degeneration, we report a decrease in the AH outflow
together with a decrease in the trabecular filtrating function,
suggestingthatlong-termOHTwasduetolateandstabletrabecular
Figure 4. Ophthalmic administration of CXCR3 antagonist decreases intraocular pressure in a rat model of ocular hypertension. (A)
A single administration of CXCR3 antagonist (NBI-74330, 1 mM, 100 mL) induces a transient decrease in intraocular pressure (n=10 in each group). (B)
When the antagonist is administrated twice, intraocular pressure remains low during 6 weeks (n=10 each); the black arrow indicates the period of
retinal and visual in vivo testing presented in Fig. 6A,B. (C) Dose-dependent effect of two administrations of CXCR3 antagonist on intraocular pressure
as tested two weeks after the treatment (n=5 each). * P,0.05, ** P,0.01. Data in graphs are presented as means 6 SEM.
doi:10.1371/journal.pone.0037873.g004
Figure 5. Ophthalmic administration of CXCR3 antagonist restores trabecular filtrating function and protects trabecular cells from
apoptosis in a rat model of ocular hypertension. (A) Aqueous humor outflow impairment in hypertensive eyes is counteracted by treatment
with CXCR3 antagonist as measured in vivo by fluorophotometry (n=10 each). (B,C,D) Trabecular filtrating function is restored by treatment with
CXCR3 antagonist as assessed by trabecular trapping of fluorescent microspheres (red), and quantitatively measured as percent of effective filtration
length (PEFL), which is more important in treated eyes (B) than in untreated hypertensive eyes (C) (n=10 each). (E,F,G) Density of apoptotic trabecular
cells is lower in eyes treated with the CXCR3 antagonist (E) than in untreated hypertensive eyes (F), as assessed by TUNEL (green) and DAPI (blue)
nuclear staining (n=10 each). ** P,0.01. (scale bar, 50 mm). Data in bar graphs are presented as means 6 SEM.
doi:10.1371/journal.pone.0037873.g005
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cellular level, we observed an increase in TC apoptosis similarly to
what is observed in glaucoma in humans [10]. Ophthalmic
treatment with NBI-74330 reduced IOP and related retinal
degeneration by restoring the trabecular filtrating function and
protecting TCs from apoptosis Even if the trabecular pathology in
primaryglaucomaiscurrentlyconsideredasadegenerativeprocess,
the relationship between glaucoma and inflammation has to be
pointed out. It is noted that no inflammatory cell infiltration was
found in rat TMs. Accordingly, our team previously found very few
inflammatorycellsintheTMofglaucomatouspatientsasassessedex
vivobyconfocalmicroscopy[9].Togetherthesefindingssuggestthat
CXCL12 acts in autocrine/paracrine manner in the TM, and that
glaucomatous trabecular degeneration is likely to develop without
involving immune cells, further confirming that NBI-74330 acts
directly on trabecular cells. Moreover, we reported in vivo that
subconjunctival injections of SDF-1(5-67) in healthy rat eyes
inducedOHT.ThetransienteffectofSDF-1(5-67)onIOPelevation
may suggest that other factors can be implicated. Though our study
focused on CXCL12, we cannot exclude that other chemokines
could also play a role in the TM regulation, such as CXCL8, CCL2
andCXCL6thatwererecentlydetectedinculturedTCs,butwhose
effects are still unknown [62].
Here we originally suggest that the chemokine CXCL12 plays a
crucial role in the initial pathogenesis of trabecular degeneration:
(i) CXCL12 acts physiologically as a protective chemokine in an
autocrine CXCL12/CXCR4 signaling mechanism; (ii) cytokine-
and MMP-related pathological overexpression and processing of
CXCL12 into SDF-1(5-67) decrease CXCL12-related CXCR4
activation and induce morphological changes and apoptosis via
CXCR3, leading to TM dysfunction, OHT, and retinal degen-
eration; and (iii) CXCR3 blockade in vivo by ophthalmic treatment
with a selective antagonist can restore trabecular function, prevent
the retinal neuropathy and protect the visual function in an animal
model of OHT. Current antiglaucoma treatment to decrease
OHT is still non-curative because it does not treat the TM
degeneration responsible for OHT that leads to retinal neurode-
generation and visual impairments. Here we propose that SDF-
1(5-67)/CXCR3 interaction may be targeted in order to treat the
causal trabecular pathology.
Supporting Information
Figure S1 CXCL12 and its truncated form SDF-1(5-67)
bind to two different chemokine receptors. Human
glaucomatous trabecular cell line HTM3 was assessed for
membrane expression of CXCR3 and CXCR4 using immuno-
flowcytometry. 3-h stimulation with exogenous CXCL12 (10 ng/
mL [1.3 nM]) decreases membrane expression of CXCR4 but not
CXCR3, whereas 3-h stimulation with SDF-1(5-67) (10 ng/mL
[1.3 nM]) decreases the membrane expression of CXCR3 but not
CXCR4; ** P,0.01. Data are presented as means 6 SEM.
(DOCX)
Figure S2 Lack of effect of a CXCR4 antagonist on
intraocular pressure in a rat model of ocular hyperten-
sion. Ophthalmic administration of a CXCR4 antagonist (AMD-
3100, 1 mM, 100 mL) in the subconjunctival space does not modify
intraocular pressure in control and surgically-induced hypertensive
rat eyes (n=10 in each group). Data are presented as means 6
SEM.
(DOCX)
Figure S3 SDF-1(5-67) increases intraocular pressure.
Two intraocular injections (black arrows) of exogenous SDF-1(5-
67) (100 ng/mL [13 nM], 5 mL) in the anterior chamber of
healthy rat eyes induce a transient ocular hypertension (n=10
each); ** P,0.01 vs. vehicle-injected eyes. Data are presented as
means 6 SEM.
(DOCX)
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